Liposomal Resveratrol and/or Carvedilol Attenuate Doxorubicin-Induced Cardiotoxicity by Modulating Inflammation, Oxidative Stress and S100A1 in Rats

Role of cytokines and inflammation in heart function during health and disease

(2018) Monika Bartekova et al.   HEART FAILURE REVIEWS

Anti-Inflammatory Effects of Resveratrol: Mechanistic Insights

(2018) Diego de Sá Coutinho et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Enoxaparin attenuates doxorubicin induced cardiotoxicity in rats via interfering with oxidative stress, inflammation and apoptosis

(2018) Reem Ali Shaker et al.   BMC Pharmacology & Toxicology

Health Effects of Resveratrol: Results from Human Intervention Trials

(2018) Sonia Ramírez-Garza et al.   Nutrients

Protective Effect of Carvedilol on Paracetamol-induced Hepatotoxicity; Role of Modulation Inflammation and Lipid Peroxidation

(2017) Heba M. Mahmoud et al.   International Journal of Pharmacology

Resveratrol mitigates lipopolysaccharide-mediated acute inflammation in rats by inhibiting the TLR4/NF-κBp65/MAPKs signaling cascade

(2017) Guangxi Wang et al.   Scientific Reports

Prophylactic supplementation of resveratrol is more effective than its therapeutic use against doxorubicin induced cardiotoxicity

(2017) Heba Samy Shoukry et al.   PLoS One

Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial

(2016) Ahmad Tashakori Beheshti et al.   CARDIOLOGY

Preventive role of carvedilol in adriamycin-induced cardiomyopathy

(2016) Rajesh Jhorawat et al.   INDIAN JOURNAL OF MEDICAL RESEARCH

Effects of carvedilol on ventricular remodeling and the expression of β 3 -adrenergic receptor in a diabetic rat model subjected myocardial infarction

(2016) Ruiying Zhang et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver

(2016) Yueli Tian et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

The emerging role of Toll-like receptor 4 in myocardial inflammation

(2016) Y Yang et al.   Cell Death & Disease

Resveratrol inhibits doxorubicin-induced cardiotoxicity via sirtuin 1 activation in H9c2 cardiomyocytes

(2016) Mi-Hua Liu et al.   Experimental and Therapeutic Medicine

Resveratrol and Cardiovascular Diseases

(2016) Dominique Bonnefont-Rousselot   Nutrients

Therapeutic potential of resveratrol in heart failure

(2015) Miranda M. Sung et al.   Annals of the New York Academy of Sciences

Resveratrol Prevents Cardiovascular Complications in the SHR/STZ Rat by Reductions in Oxidative Stress and Inflammation

(2015) Rebecca K. Vella et al.   Biomed Research International

S100A1 as a Potential Diagnostic Biomarker for Assessing Cardiotoxicity and Implications for the Chemotherapy of Certain Cancers

(2015) Ufuk Eryilmaz et al.   PLoS One

Doxorubicin Induces Sarcoplasmic Reticulum Calcium Regulation Dysfunction via the Decrease of SERCA2 and Phospholamban Expressions in Rats

(2014) Yachen Zhang et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats

(2014) Manar Hamed Arafa et al.   JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY

Resveratrol ameliorates cardiac dysfunction induced by pressure overload in rats via structural protection and modulation of Ca2+ cycling proteins

(2014) Qi Dong et al.   Journal of Translational Medicine

Resveratrol attenuates inflammation in the rat heart subjected to ischemia-reperfusion: Role of the TLR4/NF-κB signaling pathway

(2014) Jingbo Li et al.   Molecular Medicine Reports

Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis

(2014) Dinesh Vyas et al.   OncoTargets and Therapy

Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability

(2013) Salette Reis et al.   International Journal of Nanomedicine

Potential of resveratrol in the treatment of heart failure

(2013) Pema Raj et al.   LIFE SCIENCES

Doxorubicin-Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy

(2013) Filipa S. Carvalho et al.   MEDICINAL RESEARCH REVIEWS

The Role of Nitric Oxide in Doxorubicin-Induced Cardiotoxicity: Experimental Study

(2013) Ayşenur Bahadır et al.   Turkish Journal of Hematology

Targeting S100A1 in heart failure

(2012) J Ritterhoff et al.   GENE THERAPY

Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies

(2012) Yanti Octavia et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Resveratrol in cardiovascular disease: what is known from current research?

(2011) Hong Wang et al.   HEART FAILURE REVIEWS

Mechanisms and management of doxorubicin cardiotoxicity

(2011) Y. Shi et al.   HERZ

S100A1 Genetically Targeted Therapy Reverses Dysfunction of Human Failing Cardiomyocytes

(2011) Henriette Brinks et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Activation of Sirt1 by Resveratrol Inhibits TNF-α Induced Inflammation in Fibroblasts

(2011) Xiaoxia Zhu et al.   PLoS One

Pattern Recognition Receptors and Inflammation

(2010) Osamu Takeuchi et al.   CELL

S100A1: A Regulator of Striated Muscle Sarcoplasmic Reticulum Ca2+Handling, Sarcomeric, and Mitochondrial Function

(2010) Mirko Völkers et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats

(2010) Wawaimuli Arozal et al.   TOXICOLOGY

Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy

(2009) M. Sulaiman et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage

(2009) Elif Tatlidede et al.   FREE RADICAL RESEARCH

S100A1 in cardiovascular health and disease: Closing the gap between basic science and clinical therapy

(2009) Carolin Kraus et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice

(2008) Alexander Riad et al.   EUROPEAN JOURNAL OF HEART FAILURE